Literature DB >> 15956743

Myocardial relaxin counteracts hypertrophy in hypertensive rats.

Thomas Dschietzig1, Cornelia Bartsch, Till Kinkel, Gert Baumann, Karl Stangl.   

Abstract

Current findings in male relaxin knockout mice indicate antifibrotic and positive lusitropic actions of relaxin on the myocardium. We investigated in 12-month-old male spontaneously hypertensive rats (SHR) and age-matched male Wistar-Kyoto rats (WKY) whether RLX shows antihypertrophic actions as well. SHR showed left heart hypertrophy and a selective elevation of left atrial and ventricular relaxin peptide which inversely correlated with the degree of hypertrophy. In adult rat cardiomyocytes, relaxin blunted phenylephrine-induced hypertrophy by inhibiting activated ERK-1/2 kinases. In conclusion, endogenous myocardial relaxin, upregulated in left heart hypertrophy, exerts antihypertrophic effects by inhibition of activated ERK-1/2 kinases.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15956743     DOI： 10.1196/annals.1282.066

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  7 in total

Review 1.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 2.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 4.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

Review 5.  Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.

Authors:  Javier Díez; Luis M Ruilope
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2015-11-26

6.  The effects of physical exercise on plasma levels of relaxin, NTproANP, and NTproBNP in patients with ischemic heart disease.

Authors:  Matthias Heringlake; T Kox; J Poeling; S Klaus; T Hanke; N Franz; F Eberhardt; H Heinze; F P Armbruster; L Bahlmann
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

7.  Relaxin and atrial natriuretic peptide pathways participate in the anti-fibrotic effect of a melon concentrate in spontaneously hypertensive rats.

Authors:  Julie Carillon; Audrey Gauthier; Sandy Barial; Michel Tournier; Nathalie Gayrard; Anne-Dominique Lajoix; Bernard Jover
Journal:  Food Nutr Res       Date:  2016-04-12       Impact factor: 3.894
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.